Peptides
GDF15
An appetite and illness-related signaling protein whose activation and inhibition ask opposite clinical questions; animal weight loss has not reliably translated to people.
Animal receptor experiments plus human agonist and antagonist trials with different results
Also known as: Growth differentiation factor 15 · GDF-15
Practical use
Evidence interpretation and clinical context
- Write the direction beside the name
- Specify GDF15 activation, GDF15 blockade or a blood measurement.
- Prefer the human intervention result
- Do not stop at an impressive animal weight-loss figure when a human trial is available.
- Keep the disease context attached
- Reversing cancer wasting is a different goal from treating obesity.
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.
Overview
GDF15 signals through the GFRAL–RET receptor system in the hindbrain. It can reduce food intake in experimental settings. In cancer cachexia, investigators have instead tested blocking excess GDF15 to counter involuntary wasting. These are opposite directions of intervention.
Risks and limitations
Gastrointestinal adverse events were the most frequent events in human MBL949 studies. A signal associated with weight loss during serious illness is not automatically a desirable weight-loss target for healthy people.
How to read this
A blood biomarker, administering a modified GDF15 protein and blocking GDF15 with an antibody are three different things. Keep the intervention identity and direction visible.
Research explained
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.
Who was studied
Recombinant GDF15 experiments in obese mice and nonhuman primates, with receptor-identification work.
What was found
Food intake and body weight fell; removing GFRAL in mice blocked those effects. The experiments identified GFRAL and its RET coreceptor as central to the pathway.
What it cannot establish
Mechanistic animal evidence does not establish the magnitude or tolerability of human weight loss.
Read the original studyA Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons.
Who was studied
Two randomized human studies of MBL949, a modified long-acting GDF15 protein: 65 participants in phase 1 and 126 in phase 2.
What was found
Strong nonclinical weight-loss findings did not translate into meaningful weight-loss efficacy in the phase 2 study; gastrointestinal events were common.
What it cannot establish
This finding concerns the tested analogue and trial conditions, rather than proving every possible GDF15 intervention has the same result.
Read the original studyPonsegromab for the Treatment of Cancer Cachexia.
Who was studied
187 people with cancer cachexia and elevated GDF15 in a 12-week randomized trial of the blocking antibody ponsegromab.
What was found
The studied active groups gained more weight than placebo, with median between-group differences of 1.22–2.81 kg. The highest-exposure group also improved appetite-related and activity measures.
What it cannot establish
This was GDF15 inhibition in selected patients with cancer, not administration of GDF15 or a healthy-user muscle-gain trial.
Read the original studyResearch status and identity
These studies describe investigational pathway interventions. They do not establish an approved indication for administering GDF15 as a general fat-loss or longevity product.
Supporting sourceThe direction of treatment matters
The cachexia trial sought to reduce a signal that drives wasting. Its positive result cannot be cited as evidence that adding the same signal would improve health.
Supporting sourceClaims versus findings
Incorrect
The ponsegromab trial proves taking GDF15 builds muscle.
Ponsegromab blocks GDF15, and its primary outcome was body weight rather than muscle growth.
Check the evidenceCommon questions
Why do the animal and human weight-loss findings differ?
The studies show a translation gap; they do not provide a single proven explanation. Species, formulation and tolerability all need investigation.
SourceSources
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates.
Ponsegromab for the Treatment of Cancer Cachexia.
Sources checked 2026-10-01.
General education; not a personal treatment plan.